197 related articles for article (PubMed ID: 24519501)
1. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N; Kodama F; Tsuyama N; Sakata S; Takeuchi K; Ishibashi D; Koyama S; Ishii Y; Yamamoto W; Takasaki H; Hagihara M; Kuwabara H; Tanaka M; Hashimoto C; Yamazaki E; Koharazawa H; Fujimaki K; Sakai R; Fujisawa S; Ishigatsubo Y
Hematol Oncol; 2015 Mar; 33(1):9-14. PubMed ID: 24519501
[TBL] [Abstract][Full Text] [Related]
2. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
3. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
Takamatsu Y; Suzumiya J; Utsunomiya A; Maeda K; Matsuoka H; Suzushima H; Tsukada J; Shibata K; Tamura K;
Eur J Haematol; 2010 May; 84(5):391-7. PubMed ID: 20059527
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
[TBL] [Abstract][Full Text] [Related]
6. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
7. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.
Tsurumi H; Hara T; Goto N; Kanemura N; Kasahara S; Sawada M; Yasuda I; Yamada T; Shimizu M; Takami T; Moriwaki H
Hematol Oncol; 2007 Sep; 25(3):107-14. PubMed ID: 17457949
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Yasuda I; Katsumura N; Takahashi T; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2010 Jan; 136(1):65-70. PubMed ID: 19590893
[TBL] [Abstract][Full Text] [Related]
13. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
Zhai L; Guo C; Cao Y; Xiao J; Fu X; Huang J; Huang H; Guan Z; Lin T
Int J Hematol; 2010 Jan; 91(1):78-86. PubMed ID: 20033628
[TBL] [Abstract][Full Text] [Related]
15. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
[TBL] [Abstract][Full Text] [Related]
17. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
18. Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
Ohga S; Nakamura K; Shioyama Y; Sasaki T; Urashima Y; Terashima H; Honda H
Radiat Med; 2005 May; 23(3):156-61. PubMed ID: 15940061
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
20. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
